Randomized phase III trial of a neoadjuvant regimen of four cycles of adriamycin plus cyclophosphamide followed by four cycles of docetaxel (AC4-D4) versus a shorter treatment of three cycles of FEC followed by three cycles of docetaxel (FEC3-D3) in node-positive breast cancer (Neo-shorter; NCT02001506)

• Published in: Breast cancer research and treatment Vol. 201; no. 2; pp. 193 - 204
• Main Authors: Hwang, Inhwan, Kim, Jeong Eun, Jeong, Jae Ho, Ahn, Jin-Hee, Jung, Kyung Hae, Son, Byung Ho, Kim, Hak Hee, Shin, Junyoung, Lee, Hee Jin, Gong, Gyungyub, Kim, Sung-Bae
• Format: Journal Article
• Language: English
• Published: New York Springer US 01.09.2023; Springer Nature B.V
• Subjects: Antineoplastic Combined Chemotherapy Protocols - adverse effects; Breast cancer; Breast Neoplasms - pathology; Cancer research; Cancer therapies; Clinical Trial; Cyclophosphamide; Cyclophosphamide - adverse effects; Docetaxel - therapeutic use; Doxorubicin - adverse effects; Female; Fluorouracil - adverse effects; Humans; Medicine; Medicine & Public Health; NCT; NCT02001506; Neoadjuvant Therapy; Neutropenia; Oncology; Quality of Life; Treatment Outcome; Locally advanced breast cancer; Neoadjuvant; AC followed by docetaxel; FEC followed by docetaxel; Operable breast cancer

Purpose To determine whether six cycles of FEC3-D3 has a comparable efficacy to eight of AC4-D4. Methods The enrolled patients (pts) were clinically diagnosed with stage II or III breast cancer. The primary endpoint was a pathologic complete response (pCR), and the secondary endpoints were 3 year di...